
|Videos|May 4, 2017
Dr. Muggia on Targeted Therapies for Ovarian Cancer
Author(s)Franco M. Muggia, MD, PhD
Franco M. Muggia, MD, PhD, professor, Department of Medicine, NYU Langone Medical Center, discusses targeted therapies for patients with ovarian cancer.
Advertisement
Franco M. Muggia, MD, PhD, professor, Department of Medicine, NYU Langone Medical Center, discusses targeted therapies for patients with ovarian cancer.
The BRCA mutations occur in many of the patients with high-grade serous ovarian cancers, explains Muggia. For patients with low-grade serous disease, the major target is estrogen receptors—making anti-estrogen agents beneficial.
Though the drugs have been effective, researchers need to continue to increase the number of cures that are seen with this disease, states Muggia.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
2
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Dr Riedell on the Long-Term Efficacy of Tisa-Cel in R/R Follicular Lymphoma
5




































